Zika Virus: A New Therapeutic Candidate for Glioblastoma Treatment

International Journal of Molecular Sciences

Pier Giulio Conaldi¹  Giovanna Russelli¹  Gioacchin Iannolo¹  Cinzia Maria Chinnici²  Maria Giovanna Francipane²  Bruno Douradinha² 

[1] Department of Research, Istituto di Ricovero e Cura a Carattere Scientifico—Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione (IRCCS ISMETT), 90127 Palermo, Italy;Fondazione Ri.MED, 90133 Palermo, Italy;

关键词: Zika virus;    glioblastoma;    glioblastoma stem cells;    cancer stem cells;    miR34c;    neural stem cells;   

DOI  :  10.3390/ijms222010996

来源: DOAJ

【 摘 要 】

Glioblastoma (GBM) is the most aggressive among the neurological tumors. At present, no chemotherapy or radiotherapy regimen is associated with a positive long-term outcome. In the majority of cases, the tumor recurs within 32–36 weeks of initial treatment. The recent discovery that Zika virus (ZIKV) has an oncolytic action against GBM has brought hope for the development of new therapeutic approaches. ZIKV is an arbovirus of the Flaviviridae family, and its infection during development has been associated with central nervous system (CNS) malformations, including microcephaly, through the targeting of neural stem/progenitor cells (NSCs/NPCs). This finding has led various groups to evaluate ZIKV’s effects against glioblastoma stem cells (GSCs), supposedly responsible for GBM onset, progression, and therapy resistance. While preliminary data support ZIKV tropism toward GSCs, a more accurate study of ZIKV mechanisms of action is fundamental in order to launch ZIKV-based clinical trials for GBM patients.

【 授权许可】

Unknown